Selank vs Xanax: differences, evidence and safety

Selank is a seven-amino-acid peptide that eased anxiety about as much as the benzodiazepine medazepam in a 62-patient Russian study (Zozulya 2008). Xanax (alprazolam) is an FDA-approved benzodiazepine for generalized anxiety and panic disorder (Xanax label). Selank is not FDA approved, and its human evidence is three small studies; Xanax rests on placebo-controlled trials but carries a boxed warning for addiction and withdrawal.

Item	Selank	Xanax (alprazolam)
US FDA status	Not approved; no Selank product in FDA’s Drugs@FDA data (openFDA, searched 2026-10-25)	Approved 1981-10-16 (Drugs@FDA, NDA 018276); Schedule IV controlled substance
Compounding	Withdrawn from Category 2 by its nominator; FDA’s listed concern is immunogenicity and a lack of human safety data (FDA)	Not applicable; an approved prescription drug
WADA	Not named on the 2026 List; the S0 class covers substances with no government approval for human use (WADA 2026). Not named in the 2027 List advisory (USADA)	Benzodiazepines are not named on the 2026 List or in USADA’s 2027 advisory (searched 2026-10-25)
Strongest evidence	Human comparative studies, published in Russian (n=60 to 70)	Approved label; placebo-controlled RCTs
Human trials	3 published; 0 registered on ClinicalTrials.gov (searched 2026-10-25)	109 registered studies list alprazolam (ClinicalTrials.gov, 2026-10-25)
Next regulatory step	None announced	None announced
Last checked	2026-10-25	2026-10-25

Selank vs Xanax at a glance

Feature	Selank	Xanax (alprazolam)
What it is	Synthetic heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro	Benzodiazepine (1,4 benzodiazepine)
Class	Tuftsin-derived regulatory peptide	Anxiolytic; CNS depressant
Main target	GABA-A modulation in rat tissue; enkephalin breakdown	Benzodiazepine site of GABA-A receptors
Research focus	Anxiety with fatigue (asthenia)	Generalized anxiety and panic disorder
Human evidence	3 comparative studies, n=60 to 70	Placebo-controlled RCTs; label trials
Approval	Not FDA approved	FDA approved since 1981
Routes studied	Nasal (rat studies; human route not in abstracts)	Oral tablet
Onset in studies	Not reported in abstracts	Panic gains by week 1 (Ballenger 1988)
Main safety concerns	Unknown in humans; unregulated products	Addiction, dependence, withdrawal, opioid interaction

What is Selank?

Selank is a synthetic seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, (Zozulya 2001), described by its developers as an analogue of tuftsin, a natural immune peptide (Konstantinopolsky 2022). Apart from a Belgian lab analysis, every Selank study cited here comes from Russian research groups, and its three human anxiety studies were published in Russian. It is sold online as a powder or nasal spray, and a Belgian control laboratory found Selank in unknown preparations seized in 2017 and 2018 (Vanhee 2020). It is also compared with Semax on our Selank vs Semax page.

What is Xanax?

Xanax is the brand name of alprazolam, a benzodiazepine the FDA approved in 1981 (Drugs@FDA). The label indicates it for the acute treatment of generalized anxiety disorder and for panic disorder, with or without agoraphobia, in adults (Xanax label). It was the most-dispensed drug in its class in 2019, when alprazolam made up 38% of an estimated 92 million US benzodiazepine prescriptions (FDA 2020).

How they work differently

• Selank: in rat brain membranes it acted as a positive allosteric modulator of GABA binding, at a site the authors judged not the same as diazepam’s, though the two may partly overlap [Lab] (Vyunova 2018). It changed the expression of 45 of 84 neurotransmission genes in rat cortex within an hour [Animal] (Volkova 2016).
• Xanax: alprazolam binds the benzodiazepine site of GABA-A receptors and strengthens GABA’s calming signal [Approved label] (Xanax label).
• Selank: it also slowed the breakdown of enkephalins, the body’s own opioid-like peptides, in human plasma samples [Lab] (Zozulya 2001).
• Xanax: it reaches peak blood levels 1 to 2 hours after a dose and has a half-life of about 11.2 hours in healthy adults [Approved label] (Xanax label).

Evidence head-to-head: Selank vs Xanax

No study has compared Selank with alprazolam directly (PubMed, searched 2026-10-25). The figures below come from separate studies, so any comparison between the columns is cross-trial.

Outcome	Selank best evidence	Xanax best evidence
Generalized anxiety	Human comparative, n=62: anxiety relief similar to medazepam (Zozulya 2008)	Human RCT, n=184 in the two arms: HAM-A -10.9 vs -8.4 on placebo at 4 weeks (Rickels 2005)
Panic disorder	No study found (searched 2026-10-25)	Human RCT, n=526: panic-free 50% vs 28% at week 4 (Ballenger 1988)
Phobic and somatoform anxiety	Human comparative, n=60: “pronounced anxiolytic” effect vs phenazepam (Medvedev 2014)	Not a labeled use
Fatigue with anxiety	Human comparative, n=62: added antiasthenic effect (Zozulya 2008)	Fatigue is a side effect: 49% vs 42% in panic trials (label)
Versus other benzodiazepines	Similar to medazepam (Zozulya 2008)	Meta-analysis of 8 RCTs: no better than other benzodiazepines in panic (Moylan 2011)

The most promising Selank result is that it matched a benzodiazepine in the 62-patient study while also lifting fatigue (Zozulya 2008). Its limits are just as plain: the abstracts give no effect sizes and no side-effect counts, and none of the three studies is registered. Xanax’s strongest result is the multicenter panic trial, where 82% on alprazolam were rated at least moderately improved at week 4, against 43% on placebo (Ballenger 1988).

Which fits which goal?

For panic disorder, Xanax has more evidence: placebo-controlled trials and an FDA approval, against no Selank panic study found on PubMed (searched 2026-10-25). For generalized anxiety, Xanax again has more evidence, because its benefit was measured against placebo in randomized trials, while Selank was compared with another tranquilizer in small studies whose abstracts do not report blinding (Rickels 2005; Zozulya 2008). Selank’s possible edge is tolerability, since its researchers report fewer benzodiazepine side effects when it was added to phenazepam (Medvedev 2015), but no study of it outside Russia was found (PubMed, searched 2026-10-25). A clinician is the person to decide whether either fits a given patient. Our best peptides for anxiety page grades the other candidates.

Can Selank and Xanax be combined?

No controlled human study of Selank combined with alprazolam was found on PubMed or ClinicalTrials.gov (searched 2026-10-25). The closest human data is a Russian study of 70 patients in which those given Selank with the benzodiazepine phenazepam improved earlier on the HDRS scale and had fewer phenazepam side effects, including sedation and memory problems, than those on phenazepam alone [Human comparative, n=70] (Medvedev 2015). In stressed rats, Selank plus diazepam was the most effective of the groups tested at reducing anxiety [Animal, n=48] (Kasian 2017). In rat brain tissue, however, Selank blocked diazepam’s effect on GABA binding, and the joint effect differed from either substance alone [Lab] (Vyunova 2018). The Xanax label warns against combining it with other central nervous system depressants and alcohol, and an unstudied product adds an unknown to that warning.

Safety and regulatory status

Xanax’s risks are well documented. Its boxed warning covers profound sedation, breathing problems, coma and death with opioids; abuse and addiction; and dependence with withdrawal reactions that can be life-threatening (Xanax label). In the label’s panic trials, drowsiness affected 77% on Xanax against 43% on placebo, and memory impairment 33% against 22%. Some users develop a protracted withdrawal syndrome lasting weeks to more than 12 months. FDA strengthened the class boxed warning in 2020 and notes that physical dependence can develop within several days to weeks, even as prescribed (FDA 2020). In one discontinuation study, 52% of patients managed to stop alprazolam, and only 37% stayed off it for 4 weeks [Human, n=71] (Klein 1994).

Selank’s risks are mostly unknown. Its human studies report no side-effect counts in their abstracts, and FDA states it lacks important information on safety issues raised by selank acetate in humans, with a possible immunogenicity risk from aggregation and impurities in compounded products (FDA). Products sold online are unregulated, and the samples seized in Belgium were unknown preparations (Vanhee 2020). Our guide Are peptides safe? covers what FDA says about such products.

Where	Selank	Xanax (alprazolam)
US FDA	Not approved	Approved 1981; Schedule IV (label)
US compounding	Withdrawn from Category 2 (FDA)	Not applicable
Sport (WADA)	Not named; S0 may apply (WADA 2026)	Not named on the 2026 List
Pregnancy	No human data found	Neonatal sedation and withdrawal risk (label)

For athletes, a substance missing from the List is not automatically permitted; USADA explains how the non-approved class S0 works (USADA). Anyone who suspects a side effect from Selank, Xanax or any other drug or product can report it to the FDA through MedWatch.

How long do effects take in studies?

For Xanax, the panic trial found improvements in panic attacks, phobic fears and anxiety that were significant by the end of week 1 (Ballenger 1988), and the generalized anxiety trial found psychic anxiety improved by week 1 (Rickels 2005). For Selank, the abstracts give no onset time; one reports that the anti-anxiety effect lasted a week after the last dose (Medvedev 2014), and the cytokine study followed patients for 14 days (Uchakina 2008).